Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: new AstraZeneca ADC lung cancer data seen as underwhelming; William Pao’s aspirations at Pfizer; Scholar Rock’s hopes for SMA asset; Biomarin’s Roctavian launch; and Indian lighthouses deliver gains.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7 July 2023, including: new AstraZeneca PLC ADC lung cancer data seen as underwhelming; William Pao’s aspirations at Pfizer Inc.; Scholar Rock, LLC’s hopes for SMA asset; BioMarin Pharmaceutical Inc.’s Roctavian launch; and Indian lighthouses deliver gains.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "AstraZeneca’s Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study" - Scrip, 3 Jul, 2023.)
(Also see "William Pao On Pfizer’s ‘Aspirational’ Drug Development Goal, Seagen And More" - Scrip, 5 Jul, 2023.)
(Also see "Scholar Rock Looks To Augment Existing Therapies In Spinal Muscular Atrophy" - Scrip, 3 Jul, 2023.)
(Also see "Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong" - Scrip, 30 Jun, 2023.)
(Also see "Indian ‘Lighthouses’ Deliver Gains Amid Price Erosion, Rising Input Costs" - Scrip, 3 Jul, 2023.)